News

Company has announced that it has initiated a phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients.

Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.

Company has encouraged by two recent reports that emphasise the importance of protein profiling to improve outcomes in cancer treatment.

Nimbus Therapeutics will receive an upfront payment of $400 million, with the potential to receive an additional $800 million in development-related milestones over time.

Do cancer cells synthesize the parts for new cells or scavenge them from the environment?

Mouse study suggests possibility of curbing early synapse loss in Alzheimer’s.

How proteins present in tick saliva prevent the immune system from running amok.

Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.

Researchers at TSRI and Salk Institute have discovered 'Outlier' enzymes that could offer new targets to treat type 2 diabetes and inflammatory disorders.

Thermo Fisher Scientific and Affymetrix, has announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion.